Kevan Clemens - Jul 1, 2021 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role
Director
Signature
/s/ Brian G. Drazba, as attorney in fact
Stock symbol
MEIP
Transactions as of
Jul 1, 2021
Transactions value $
$0
Form type
4
Date filed
7/6/2021, 06:55 PM
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Stock Option (Right to Buy) Award $0 +50K $0.00 50K Jul 1, 2021 Common Stock 50K $2.95 Direct F1
holding MEIP Stock Option (Right to Buy) 12.7K Jul 1, 2021 Common Stock 12.7K $6.47 Direct F2
holding MEIP Stock Option (Right to Buy) 20K Jul 1, 2021 Common Stock 20K $1.57 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 1, 2021 Common Stock 40K $1.36 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 1, 2021 Common Stock 40K $2.83 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 1, 2021 Common Stock 40K $4.28 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 1, 2021 Common Stock 40K $2.52 Direct F2
holding MEIP Stock Option (Right to Buy) 50K Jul 1, 2021 Common Stock 50K $3.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest in equal monthly installments over twelve months.
F2 All of such options are presently exercisable.